Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review

Horace Massa; Anindyt M Nagar; Athanasios Vergados; Panagiotis Dadoukis; Sudeshna Patra; Georgios D Panos

doi:10.1177/0300060518816884

Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review

J Int Med Res. 2019 Jan;47(1):31-43. doi: 10.1177/0300060518816884. Epub 2018 Dec 16.

Authors

Horace Massa^{1

2}, Anindyt M Nagar^{3

2}, Athanasios Vergados³, Panagiotis Dadoukis³, Sudeshna Patra³, Georgios D Panos³

Affiliations

¹ 1 Department of Ophthalmology, Geneva University Hospitals, Geneva, Switzerland.
² *These authors contributed equally to this work.
³ 2 Eye Treatment Centre, Whipps Cross University Hospital, Barts Health NHS Trust, London, UK.

Abstract

Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy and may lead to severe visual loss. In this review, we describe the pathophysiology of DMO and review current therapeutic options such as macular laser photocoagulation, anti-vascular endothelial growth factor agents, and steroid implants with a focus on the new fluocinolone acetonide implant, ILUVIEN®. The results of the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) studies are also presented together with the results of real-world studies to support the clinical use of ILUVIEN® in achieving efficient resolution of DMO and improving vision and macular anatomy in this challenging group of patients.

Keywords: Diabetic macular oedema; ILUVIEN; anti-VEGF agents; diabetes; diabetic retinopathy; fluocinolone acetonide; intravitreal injections; steroid implant.

Publication types

Review

MeSH terms

Angiogenesis Inhibitors / pharmacokinetics
Angiogenesis Inhibitors / pharmacology*
Anti-Inflammatory Agents / pharmacokinetics
Anti-Inflammatory Agents / pharmacology*
Diabetic Retinopathy / complications
Diabetic Retinopathy / metabolism
Diabetic Retinopathy / physiopathology
Diabetic Retinopathy / therapy*
Drug Implants / chemistry*
Fluocinolone Acetonide / pharmacokinetics
Fluocinolone Acetonide / pharmacology*
Humans
Intravitreal Injections
Light Coagulation / methods
Low-Level Light Therapy / methods
Macular Edema / etiology
Macular Edema / metabolism
Macular Edema / physiopathology
Macular Edema / therapy*
Patient Safety
Treatment Outcome
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Vascular Endothelial Growth Factor A / metabolism

Substances

Angiogenesis Inhibitors
Anti-Inflammatory Agents
Drug Implants
VEGFA protein, human
Vascular Endothelial Growth Factor A
Fluocinolone Acetonide